Summary & Overview
HCPCS J1954: Leuprolide Acetate Injectable Depot, 7.5 mg
HCPCS Level II code J1954 denotes injection of leuprolide acetate for depot suspension (Lutrate Depot), 7.5 mg, a long‑acting GnRH agonist used in multiple clinical contexts including hormone-sensitive conditions. Nationally, accurate coding for depot hormone therapies affects medication utilization tracking, payer coverage determinations, and facility billing for injectable specialty drugs. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the clinical use and billing context for HCPCS Level II code J1954, typical sites of service where this depot injection is administered, common modifiers and administrative considerations, and how major payers approach coverage and claims adjudication for depot GnRH agonists. The publication also provides benchmarking perspectives and policy updates relevant to injectable depot medications, operational guidance for accurate service line reporting, and common administrative pitfalls to avoid. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1954 represents an injection of leuprolide acetate for depot suspension (Lutrate Depot), 7.5 mg. This code is used to report administration of a long‑acting gonadotropin‑releasing hormone (GnRH) agonist formulated for depot release.
-
Service type: Medication administration (injectable depot therapy)
-
Typical site of service: Outpatient clinic or physician office; may also be administered in ambulatory surgery centers or other outpatient infusion settings
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male with prostate cancer or a premenopausal woman with endometriosis receiving a depot GnRH agonist. The patient presents to an ambulatory infusion clinic, urology clinic, gynecology clinic, or outpatient hospital setting for a scheduled intramuscular injection of J1954 (leuprolide acetate for depot suspension, 7.5 mg). The visit workflow includes identity and allergy verification, review of indication and prior dosing, informed consent for the depot injection, preparation of the medication per manufacturer instructions, aseptic intramuscular administration (usually in the gluteal or deltoid muscle), observation for immediate adverse reactions for 15–30 minutes if indicated, documentation of lot number and expiration, and scheduling the next depot dose (often monthly). Typical sites of service are outpatient clinic, physician office, ambulatory infusion center, or outpatient hospital department. Common clinical reasons for use include androgen deprivation for prostate cancer, suppression of ovarian function for endometriosis or uterine fibroids, and management of central precocious puberty in pediatric patients (other strengths/formulations used for pediatrics). Documentation should include diagnosis linking, date and route of administration, medication lot and expiration, amount administered, and any applicable modifier to reflect payer-specific circumstances such as administration by a different clinician or wastage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |